TCRT Alaunos Therapeutics, Inc.
-
Alaunos Therapeutics Reported Earnings
Friday, August 14, 2026 · 12:00 AM ET
Alaunos Therapeutics (TCRT) reported a loss of $0.41 per share on revenue of $0.00 million for the . .
Alaunos is a clinical-stage oncology-focused cell therapy company, focused on developing T-cell receptor (TCR) therapies based on its non-viral Sleeping Beauty gene transfer platform and its unique cancer hotspot Library, covering common tumor-related mutations in key oncolytic genes including KRAS, TP53 and EGFR.
Reported Earnings
($0.41)
Earnings Whisper®
—
Consensus Estimate
—
Earnings Surprise
Earnings Growth
Reported Revenue
—
Revenue Estimate
—
Revenue Surprise
Revenue Growth—